GENMAB A/S

GMAB
Delayed Quote. Delayed  - 10/20 10:59:35 am
2928DKK +0.62%

Turn to zoom
Prev.2910.0000
Open2910.0000
High2962.0000
Low2903.0000
Volume104 080
Latest news
13h ago
1d ago
1d ago
1d ago
Chart GENMAB A/S
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBullish
Resistance3 0183 1003 062
Spread/Res.-3,0%-5,5%-4,4%
Spread/Supp.4,2%14%23%
Support2 8092 5662 384
Financials
Sales 2021 8 090 M 1 267 M 1 267 M
Net income 2021 2 394 M 375 M 375 M
Net cash 2021 14 748 M 2 309 M 2 309 M
P/E ratio 2021 83,3x
Yield 2021 -
Capitalization 191 B 29 961 M 29 978 M
EV / Sales 2021 21,8x
EV / Sales 2022 16,2x
Nbr of Employees 1 029
Free-Float 94,9%
Company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma...

>> Read more
Sector :
Bio Therapeutic Drugs
Calendar :
2021-11-03 Earnings Release
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 928,00 DKK
Average target price 2 804,30 DKK
Spread / Average Target -4,22%